David Planchard, Thoracic Oncologist, Professor at the University Paris Saclay and Head of the Thoracic Cancer Group at the Gustave Roussy, shared a post on X:
“Superb presentation by Benjamin Besse on the results of the Phase III LATIFY study. Unfortunately, the trial was negative, despite a potential benefit in 7% of patients who require molecular characterization…”
Julien Mazieres, Head of Thoracic Diseases Department at the University Hospital Center of Toulouse, shared this post, adding:
“Same feeling than you and Benjamin. Some patients also derived prolonged benefit from durva + ceralasertib in the Pioneer trial. Need to be investigated.”
Other articles featuring Julien Mazieres.
